Filgrastim

證據等級: L5

預測適應症: 10 個

Filgrastim: From Neutropenia (G-CSF Supportive Care) to Primary Platelet Release Disorder

One-Sentence Summary

Filgrastim is a recombinant human G-CSF, clinically used to stimulate neutrophil recovery and mobilize hematopoietic stem cells in the supportive-care setting (e.g., around chemotherapy and stem cell transplantation). The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but the supporting evidence is weak — the 13 clinical trials identified all use Filgrastim only as a supportive agent for stem cell mobilization/neutrophil recovery in unrelated transplant protocols, and only 1 publication loosely touches on the topic, with no evidence directly evaluating Filgrastim for this indication.

⚠️ Note on original indication: The evidence pack does not contain a confirmed regulatory-approved indication text for Filgrastim (original_indications is empty, original_moa is a data gap). The "Neutropenia" framing above is inferred from repeated context in the trial relevance annotations (G-CSF used for "幹細胞動員/嗜中性球恢復") and should be confirmed against an authoritative label before use in any external-facing document.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (regulatory data gap) — G-CSF is contextually referenced as supporting neutrophil recovery/stem cell mobilization
Predicted New Indication	Primary Release Disorder of Platelets
TxGNN Prediction Score	99.99% (rank 48 among all predictions)
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in the evidence pack). Based on the contextual information available, Filgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) whose known pharmacology is to stimulate proliferation and differentiation of granulocyte precursor cells and to mobilize hematopoietic stem cells — a mechanism used clinically to support neutrophil recovery after myelosuppressive therapy and to mobilize stem cells before transplantation.

Primary release disorder of platelets, by contrast, is a defect in platelet granule secretion machinery (pathways such as ADP/TXA2 signaling and granule exocytosis). The evidence pack's own mechanistic analysis states explicitly that there is no direct biological link between G-CSF signaling and platelet granule release pathways. The high TxGNN score most likely reflects an indirect association learned from the knowledge graph — both concepts cluster under broad "hematologic disease/hematopoiesis" nodes — rather than a genuine shared mechanism.

Consistent with this, all 13 clinical trials retrieved for this indication are studies of allogeneic/autologous hematopoietic stem cell transplantation for unrelated conditions (leukemia, lymphoma, sarcoma, MS, SLE, COVID-19), in which Filgrastim/G-CSF appears only as a supportive-care agent for stem cell mobilization or post-transplant neutrophil recovery — not as an investigational treatment for platelet release disorders. Several trials were explicitly graded "C" (low relevance) during triage. This prediction should be treated as hypothesis-generating only, not as evidence of therapeutic plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00281879	Phase 2	Terminated	200	Unrelated donor HSCT for hematologic malignancies; G-CSF used for stem cell mobilization/neutrophil recovery, not for platelet disorders (graded low relevance)
NCT00043979	Phase 2	Completed	60	Allogeneic/syngeneic HSCT for pediatric sarcomas; G-CSF as supportive agent only (graded low relevance)
NCT00354172	Phase 2	Terminated	16	Umbilical cord blood transplant + NK cells for myeloid leukemia not in remission
NCT00923364	Phase 2	Completed	19	Reduced-intensity HSCT for patients with GATA2 mutations
NCT02646098	Phase 2	Completed	64	CD34+ selected vs. unselected autologous HSCT in MCL/DLBCL; G-CSF used for stem cell collection (graded low relevance)
NCT05436418	Phase 1/2	Recruiting	260	Post-transplant cyclophosphamide + sirolimus/MMF for GVHD prophylaxis after PBSCT
NCT05170828	Phase 1	Withdrawn	0	Cryopreserved HLA-mismatched unrelated donor bone marrow transplant with PTCy
NCT00076752	Phase 2	Completed	9	Autologous HSCT for severe systemic lupus erythematosus
NCT04540120	Phase 2	Terminated	49	Dapansutrile (NLRP3 inhibitor) for moderate COVID-19/cytokine release syndrome (unrelated to Filgrastim mechanism)
NCT06859424	Phase 2	Recruiting	358	Post-transplant cyclophosphamide-based GVHD prophylaxis in mismatched unrelated donor PBSCT

None of the above trials directly evaluate Filgrastim as a treatment for platelet release disorders; all identified uses are supportive-care/stem cell mobilization in unrelated transplant contexts.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29770133	2018	Cohort study	Frontiers in Immunology	G-CSF mobilization in healthy stem cell donors preferentially mobilizes lymphocyte subsets; does not address platelet granule release function

Norway Market Information

Filgrastim is currently not marketed in Norway (0 authorizations on record). No product license or approved indication text is available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Important flag: The evidence pack marks TFDA/product-label warnings and contraindications as a Blocking-severity data gap — this must be resolved (via TFDA label retrieval and parsing) before any safety assessment (S1 stage) can proceed. Drug interaction data was also queried with no results found.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the evidence pack's own mechanistic and clinical-trial review finds no direct biological or clinical link between Filgrastim's known G-CSF activity and platelet granule release disorders — all retrieved trials use Filgrastim only as a supportive agent in unrelated transplant protocols, and only one loosely related observational study exists. Combined with a Blocking-severity gap in safety/label data, this candidate does not meet the bar to advance beyond signal detection (S0).

To proceed, the following is needed:

Retrieve and parse the official TFDA/product label for warnings, contraindications, and DDI (Blocking gap, DG001)
Obtain confirmed mechanism-of-action and approved-indication data from DrugBank (High-severity gap, DG002)
Seek preclinical or mechanistic evidence directly linking G-CSF/granulocyte signaling to platelet granule secretion pathways, if such a hypothesis is to be pursued further
Re-triage the "pending" relevance-graded trials to confirm none provide direct evidence before any re-evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.